Arvinas Inc
NASDAQ:ARVN
Arvinas Inc
NASDAQ:ARVN
Price:
32.82 USD
1.2%
Market Closed
Updated:
May 4, 2024
Section:
Relative Value
The Relative Value of one
ARVN
stock under the Base Case scenario is
11.94
USD.
Compared to the current market price of 32.82 USD,
Arvinas Inc
is
Overvalued by 64%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
ARVN
Relative Value
Base Case
11.94
USD
Overvaluation 64%
Valuation Multiples
Multiples Across Competitors
ARVN Competitors Multiples
Arvinas Inc Competitors
Arvinas Inc Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| US |
|
Arvinas Inc
NASDAQ:ARVN
|
2.2B USD | 28.4 | -6.1 | -2.4 | -2.4 | |
| JP |
N
|
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
|
776 550.9T JPY | 4 211 733 | -5 347 888.9 | -5 459 134.4 | -5 046 864.6 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
698.5B USD | 19.4 | 113.8 | 55.8 | 63.5 | |
| UK |
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP | 578.3 | -15 783.5 | 3 846.3 | 17 702.3 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
3.8T DKK | 16.3 | 45.3 | 33.1 | 36.1 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
359.3B USD | 4.2 | 9.3 | 11.5 | 15 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
322.8B USD | 5.3 | 140 | 33.3 | 52.8 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
186.8B GBP | 5.1 | 39.4 | 140.7 | 225.6 | |
| CH |
|
Novartis AG
SIX:NOVN
|
179.8B CHF | 4.3 | 13.4 | 9.8 | 16.2 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
173.2B CHF | 3 | 15.1 | 8.6 | 10.2 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
157B USD | 2.9 | -508.1 | 12.6 | 20.1 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
You don't have any saved screeners yet
